Literature DB >> 7139531

Hepatoid yolk sac tumor of the ovary (endodermal sinus tumor with hepatoid differentiation): a light microscopic, ultrastructural and immunohistochemical study of seven cases.

J Prat, A K Bhan, G R Dickersin, S J Robboy, R E Scully.   

Abstract

Seven cases of ovarian yolk sac tumor (endodermal sinus tumor) with patterns resembling those of hepatocellular carcinoma were encountered in patients 7-43 years of age. Two of the patients had gonadal dysgenesis with a 46XY karyotype. At operation three tumors were confined to the ovary and four were associated with intra-abdominal metastases. Two of the Stage I tumors recurred within one year. The hepatoid pattern was a prominent feature of all the tumors and was exclusive in four of them. In one specimen it merged almost imperceptibly with a polyvesicular vitelline pattern. The hepatoid component of the tumors was characterized by discrete masses, nests and/or broad bands of large polyhedral cells with central nuclei and prominent nucleoli; gland-like spaces, some of which contained mucin, were occasionally evident. Each tumor contained numerous PAS-positive, diastase-resistant intracytoplasmic and extracytoplasmic hyaline bodies. Alpha-fetoprotein and alpha-1-antitrypsin were identified by immunoperoxidase and immunofluorescence techniques in four tumors and albumin in two. Immunoperoxidase stains for chorionic gonadotropin were negative in four cases. Ultrastructural analysis of two specimens disclosed features similar to those of hepatocellular carcinoma.

Entities:  

Mesh:

Year:  1982        PMID: 7139531     DOI: 10.1002/1097-0142(19821201)50:11<2355::aid-cncr2820501122>3.0.co;2-7

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  11 in total

1.  Plasma protein and apolipoprotein synthesis by human yolk sac carcinoma cells in vitro.

Authors:  R E Lanford; D L Bronson; L E Estlack; F H Wians
Journal:  In Vitro Cell Dev Biol       Date:  1991-03

2.  alpha-Fetoprotein-producing adenocarcinoma of the pancreas presenting focal hepatoid differentiation.

Authors:  S Tanno; T Obara; T Fujii; T Izawa; Y Mizukami; Y Saitoh; H Ura; Y Kohgo
Journal:  Int J Pancreatol       Date:  1999-08

Review 3.  Hepatoid adenocarcinoma: a distinctive histological subtype of alpha-fetoprotein-producing lung carcinoma.

Authors:  H Ishikura; M Kanda; M Ito; K Nosaka; K Mizuno
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

4.  Hepatoid adenocarcinoma of the urinary bladder.

Authors:  A Lopez-Beltran; R J Luque; A Quintero; M J Requena; R Montironi
Journal:  Virchows Arch       Date:  2003-03-25       Impact factor: 4.064

5.  Combined choriocarcinoma, hepatoid adenocarcinoma, small cell carcinoma and tubular adenocarcinoma in the oesophagus.

Authors:  T Motoyama; M Higuchi; J Taguchi
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

6.  Alpha-fetoprotein (AFP)-producing ovarian tumor in an elderly woman.

Authors:  Seiji Isonishi; Asako Ogura; Takako Kiyokawa; Michiko Suzuki; Shiro Kunito; Masanori Hirama; Toshiaki Tachibana; Kazuhiko Ochiai; Tadao Tanaka
Journal:  Int J Clin Oncol       Date:  2009-02-20       Impact factor: 3.402

7.  Prognostic significance of histopathological subtypes in stage I pure yolk sac tumour of the ovary.

Authors:  H Sasaki; M Furusato; S Teshima; T Kiyokawa; A Tada; S Aizawa; T Yamabe; S Tsugane; Y Terashima
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

8.  Hepatoid Adenocarcinoma of the Urachus.

Authors:  Daniel Fernando Gallego; Carlos Muñoz; Carlos Andrés Jimenez; Edwin Carrascal
Journal:  Case Rep Pathol       Date:  2016-10-10

9.  Bone metastases as initial presentation of hepatocellular carcinoma.

Authors:  Luzdivina Monteserin; Alicia Mesa; Maria Soledad Fernandez-Garcia; Arantza Gadanon-Garcia; Manuel Rodriguez; María Varela
Journal:  World J Hepatol       Date:  2017-10-18

10.  Classification of human ovarian tumors.

Authors:  R E Scully
Journal:  Environ Health Perspect       Date:  1987-08       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.